FDA CBER Office of Therapeutic Products (OTP) Advanced Manufacturing and Analytical Technologies (AMAT) for Regenerative Medicine Therapies (RMT) Workshop – Catapult’s regulatory round-up
On the 14th of March 2023, The FDA’s Center for Biologics Evaluation and Research (CBER) Office of Therapeutic Products (OTP) will host a virtual workshop for FDA staff and cell and gene therapy stakeholders to obtain specialised knowledge from experts in the field of advanced manufacturing and analytical technologies (AMAT) for regenerative medicine therapies (RMT), discuss innovative manufacturing technologies and alternative testing methods, and share experiences, challenges, and best practices critical for chemistry, manufacturing, and controls (CMC) of cellular and gene therapies and tissue engineered medical products.
Please find more details on this event including how to register, here.
Published on the 3rd of March 2023 in Catapult’s regulatory round-up for february 2023.
OpenEdition vous propose de citer ce billet de la manière suivante :
adelage (22 décembre 2023). FDA CBER Office of Therapeutic Products (OTP) Advanced Manufacturing and Analytical Technologies (AMAT) for Regenerative Medicine Therapies (RMT) Workshop – Catapult’s regulatory round-up. ELSIBI. Consulté le 12 octobre 2026 à l’adresse https://doi.org/10.58079/vezf
